GO
Loading...

Johnson & Johnson

More

  • Fighting Diabetes and More Friday, 14 Sep 2007 | 12:30 PM ET

    Could a new pharmaceutical partnership be the best way to trade the rise in diabetes? In Thursday’s Web.Extra the traders reveal how to play the latest news. Also get their trades on hard drive behemoths Western Digital and Seagate.

  • Your First Move For Thursday Sept. 13th Thursday, 13 Sep 2007 | 3:41 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Broken Baby Boomers Wednesday, 12 Sep 2007 | 8:36 PM ET

    In Wednesday’s Sea Change, Pete Najarian brings you a trade so good it will leave you weak in the knees.

  • ImClone's New CEO: Already Repeating The Past? Wednesday, 12 Sep 2007 | 2:26 PM ET

    Recently I blogged about the hiring of a new CEO at ImClone Systems and the unique clause in his contract requiring him to buy half-a-million dollars worth of stock in the company. My suspicion was that ImClone Chairman and billionaire shareholder Carl Icahn had a hand in that.

  • Inverness Passes Cramer's Test Wednesday, 12 Sep 2007 | 11:50 AM ET

    As far as he's concerned, there are plenty of reasons to own this medical diagnostics company.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Amgen, J&J Win Key Vote on Curbing Anemia Drugs Tuesday, 11 Sep 2007 | 5:01 PM ET
    The sign outside Amgen Inc.'s entrance. Thousand Oaks, Calif.

    A panel of advisers to U.S. health regulators voted on Tuesday to reject new restrictions on anemia drugs, a win for drugmakers Amgen and Johnson & Johnson .

  • Medicare Urged to Reimburse More for Anemia Drugs Tuesday, 11 Sep 2007 | 12:36 PM ET

    Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.

  • FDA Meetings And Latest On Biotech Front Tuesday, 11 Sep 2007 | 10:59 AM ET

    So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.

  • Stocks Get a Lift, Street on Fed Watch Tuesday, 11 Sep 2007 | 8:53 AM ET

    Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.

  • Heart Attack Victims Do Worse on Drug Stents: Study Tuesday, 4 Sep 2007 | 12:32 PM ET

    Patients given drug-coated stents after an acute heart attack are nearly five times more likely to die six months to two years later than those with bare metal forms of the arterial scaffolding, research showed on Tuesday.

  • Court Clears Way for J&J to Sue Over Failed Guidant Deal Thursday, 30 Aug 2007 | 12:46 PM ET

    A U.S. court dismissed some claims in a lawsuit filed by Johnson & Johnson over its failed bid for Guidant.

  • Sector Rotation for Dummies Thursday, 30 Aug 2007 | 11:22 AM ET

    There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift money from one to the other.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Warren Buffet

    Warren Buffett's Berkshire Hathaway has just revealed its portfolio holdings for the second quarter.  New additions:  Bank of America and Dow Jones, plus increased stakes in some healthcare names.

  • So J&J Thinks it Can Dance Friday, 17 Aug 2007 | 1:46 PM ET

    At CNBC we use -- among others -- a couple of primary business news wire services -- NewsEdge, part of Thomson, and Relegence, part of AOL.

  • ImClone's New CEO: Is Buying Company Stock Good Idea? Friday, 10 Aug 2007 | 10:35 AM ET
    ImClone

    Late Thursday, ImClone Systems announced it has finally hired a permanent CEO. It'd been without one for about two years. The biotech company which makes the cancer drug Erbitux and became reluctantly famous in the Martha Stewart stock-trading case tapped a guy named John Johnson for the role.

  • Johnson & Johnson Puts Red Cross In Legal "Cross Hairs" Thursday, 9 Aug 2007 | 12:11 PM ET
    Johnson & Johnson

    Johnson & Johnson, the drug/medical device/consumer health products company reeling from a plunge in sales of its anemia drug, Procrit, and its drug-coated stent, Cypher, is going to court. Not to defend a lucrative pharmaceutical patent, but to get The Red Cross to stop using its red cross logo on certain marketed products like humidifiers and grooming tools.

  • Johnson & Johnson Sues Red Cross Over Use of Emblem Thursday, 9 Aug 2007 | 10:27 AM ET

    Johnson & Johnson, the pharmaceutical giant which uses a Red Cross as its trademark, filed a lawsuit Wednesday against the American Red Cross, demanding that the charity halt the use of the red cross symbol on products it sells to the public.

  • The market's wild swings are expected to continue through the summer, analysts say, but investors should take advantage of the volatility instead of fearing it. "There's no reason to think these 100, 200-point swings won't continue," said Rob Brown, chief investment officer at Genworth Financial.  "That provides an investment opportunity."

  • Sudden Death Wednesday, 1 Aug 2007 | 8:39 PM ET

    ZymoGenetics, Cameco and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Big Pharma's New Business Model? Wednesday, 1 Aug 2007 | 3:27 PM ET
    Sanofi Aventis

    As several of the major pharmaceutical companies struggle through a period of a relative dearth of big, new products, the job casualties and the share buybacks are piling up this earnings season. Today, Sanofi-Aventis is joining the group. The French drugmaker announced it will buy back more than $4 billion of its stock and get rid of even more sales reps.